FDA Withdrawing Three Modernization Act Direct-To-Final Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA expects to withdraw direct-to-final rules regarding 30-day notices/135-day premarket approval application supplements and medical device reporting in the next few weeks, agency staffers say. The actions follow the July 31 withdrawal of a direct-to-final rule on humanitarian device exemptions.